VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | Narsoplimab for TA-TMA

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses the use of narsoplimab, a monoclonal antibody targetting mannan-binding lectin serine protease 2 (MASP-2), for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), an endothelial damage syndrome that’s increasingly found as a complication of autologous and allogeneic hematopoietic cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter